StockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)
Equities research analysts at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.00 on Wednesday. The company has a market capitalization of $100,084.00, a P/E ratio […]
More Stories
Transportation Department to Spend Nearly $1 Billion Toward Road Safety
By Naveen Athrappully Transportation Secretary Sean P. Duffy has announced almost $1 billion in funding to “make roads safer for...
Wyoming Congresswoman Who Ousted Liz Cheney Launches Senate Bid
By Bill Pan Rep. Harriet Hageman (R-Wyo.) is running for the Wyoming Senate seat being vacated by Republican Sen. Cynthia...
US Consumers Grow More Optimistic About Future Finances, Recession Fears Retreat
By Tom Ozimek U.S. consumers grew more hopeful about their future financial prospects in December and edged away from worst-case...
ICE Arrests 101 Illegal Alien Truckers in California
By Naveen Athrappully Authorities have arrested 101 illegal immigrant truck drivers from California highways under Operation Highway Sentinel, Immigration and...
Florence Pugh: Net Worth, Salary, and Relationship with Finn Cole
British movies, blockbusters, and even Marvel movies have enabled Florence Pugh to have a strong career in Hollywood. She is...
Macron Affirms Support for Greenland Sovereignty Amid US Interest in Annexation
By Rachel Roberts French President Emmanuel Macron has reaffirmed his support for the sovereignty of the Danish territory of Greenland...